Vifor Pharma Acquires Inositec


Vifor Pharma, a St. Gallen, Switzerland-based global pharma company, is to acquire Inositec AG, a Zurich Switzerland-based developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001. Inositec will receive an upfront payment of CHF 20 million and be eligible for success based clinical earn-out payments in the low triple digit million range.

Led by Mattias Ivarsson, Founder and Chief Executive Officer, Inositec is advancing INS-3001, which is being developed in non-dialysis vascular and cardiovascular calcification disorders, such as CKD-associated PAD and Aortic Valve Stenosis (AVS).

With INS-3001, Vifor Pharma will further strengthen its nephrology portfolio helping patients suffering from accelerated vascular calcification disorders at all stages of chronic kidney disease (CKD).

With INS-3001 daily subcutaneous dosing, patients with earlier stages of vascular calcification can be optimally treated, while end-stage kidney disease patients will benefit from the three times per week dosing regimen of SNF472, a novel, first-in-class inhibitor of vascular calcification in phase-III, developed for the treatment of calcific uremic arteriolopathy (CUA) and Peripheral Artery Disease (PAD) in patients with end-stage kidney disease developed by Sanifit.

Led by Abbas Hussain, Chief Executive Officer, Vifor Pharma Group is a global pharmaceuticals company which aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).